Loading...
•
Mar 31, 2023
Vanda Q1 2023 Earnings Report
Reported financial and operational results, noting a revenue increase and a shift to net income.
Key Takeaways
Vanda Pharmaceuticals reported a total revenue of $62.5 million for Q1 2023, a 4% increase compared to Q1 2022. The company achieved a net income of $3.3 million, a significant improvement from the net loss of $6.4 million in the same period last year. Vanda is also preparing for multiple regulatory submissions.
Total revenues for Q1 2023 reached $62.5 million, reflecting a 4% increase year-over-year.
HETLIOZ® net product sales increased by 7% to $39.6 million due to inventory stocking at specialty pharmacy customers.
Fanapt® net product sales slightly decreased by 1% to $22.9 million.
Net income improved to $3.3 million, compared to a net loss of $6.4 million in the prior year.
Revenue by Segment
Forward Guidance
Vanda is unable to provide 2023 financial guidance due to uncertainties surrounding the U.S. market for HETLIOZ® related to patent litigation and the at-risk launch of a generic version.
Challenges Ahead
- HETLIOZ® net product sales will likely decline in future periods.
- Decline may be significant.
- Uncertainties surrounding the U.S. market for HETLIOZ®.
- Ongoing HETLIOZ® patent litigation.
- At-risk launch of a generic version of HETLIOZ®.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...